Business
Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
MELBOURNE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercialization, expand clinical trial activity and execute on existing revenue opportunities. Gelteq intends to use the proceeds of the financing to advance its key strategic initiatives, including scaling up clinical trial programs as Gelteq advances its pharmaceutical products through regulatory pathways and
About this update from Gelteq Limited
[{"type":"image","alt":"Gelteq Limited","displaySize":"","headline":null,"caption":"Gelteq Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sKolMM.bRjvkyz9XOxielA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43","width":300,"height":45},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/sKolMM.bRjvkyz9XOxielA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43","width":300,"height":45}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercialization, expand clinical trial activity and execute on existing revenue opportunities.","length":282,"tagName":"p"},{"type":"text","content":"Gelteq intends to use the proceeds of the financing to advance its key strategic initiatives, including scaling up clinical trial programs as Gelteq advances its pharmaceutical products through regulatory pathways and ramping up commercialization of its nutraceutical products. Gelteq believes the financing will strengthen its operational scalability and enable the Company to accelerate sales execution across key markets. In addition, the proceeds are expected to enable Gelteq to effectively deploy greater resources across revenue-generating opportunities, supporting both ongoing trials and the transition of key products into scalable commercial programs.","length":662,"tagName":"p"},{"type":"text","content":"“This debt financing marks an important step forward in advancing our commercial strategy,” said Nathan Givoni, CEO of Gelteq. “With additional growth capital now secured, we believe we are well-positioned to accelerate our clinical programs, scale operations, and drive broader market adoption of our Gelteq® technology. The Company has invested significantly in R&D to establish and validate our technology, and this financing enables us to further accelerate our transition toward commercialization, revenue generation, and market expansion.”","length":549,"tagName":"p"},{"type":"...